NEW YORK, July 27- Cellomics, a Pittsburgh-based maker of cell-imaging technology, said recently that it sold its ArrayScan HCS System to Vertex Pharmaceuticals of Cambridge, Mass.
The ArrayScan Sytem is an automated system designed to measure and analyze cell activity as a way of determining function. The system can also be used to determine whether a drug is toxic or efficacious, Cellomics said.
The company did not disclose the amount Vertex paid for the system. To date, Cellomics has placed systems in nine out of ten of the leading pharmaceutical companies.
In addition to ArrayScan, Cellomics is also developing other screening and bioinformatics products for cell analysis.
Earlier this month, Cellomics acquired Momentum Healthcare, a developer of drug discovery software.